IBM gave investors a one-two punch this week that lit a fire under its stock. On Thursday the company unveiled what it calls the world’s first sub-1-nanometer chip technology — a 0.7-nanometer (7-Ångström) node built with a nanstack architecture. Then it followed up with a security partnership between its Red Hat subsidiary and Deloitte to expand the Lightwell initiative. By Friday’s close, shares had jumped 4.75% to €237.95, breaking decisively above the 200-day moving average at €235.90.
The nanstack design promises up to 50% more processing power or 70% less energy consumption compared with IBM’s current 2‑nm chip. Roughly 100 billion transistors can be packed onto an area the size of a fingernail — double the density of its predecessor. For an AI world that guzzles electricity, that efficiency gain is critical. IBM vice‑chairman Gary Cohn has highlighted the staggering energy demands of AI infrastructure, and these chips are engineered to ease that burden.
Yet the euphoria comes with a five‑year asterisk. IBM itself estimates that mass production is at least half a decade away. That long timeline exposes the company to intense competition from the likes of TSMC, Intel and Samsung, all of which are racing to commercialize similar nodes. So far IBM has not named a manufacturing partner for the nanstack process — an open question that could determine whether this breakthrough ever leaves the lab.
Alongside the hardware push, the Lightwell alliance with Deloitte tackles a different layer of the AI stack: software security. Modern generative AI can spot code vulnerabilities in seconds, so Lightwell combines automated bug hunting with virtual patching to shrink the gap between discovery and remediation. Deloitte contributes its expertise in secure architecture design. The initiative aims to protect open‑source software from automated cyberattacks, a growing threat as enterprise AI adoption accelerates.
Should investors sell immediately? Or is it worth buying IBM?
Wall Street has taken notice. The consensus analyst rating on IBM is a “Moderate Buy,” with a price target of €257.24 — roughly 8% above the current level. JPMorgan upgraded the stock to “Overweight” on June 23, citing growing tailwinds from Red Hat and OpenShift in the second half of 2026. At a recent market price of €238.40, the shares remain about 18% below their 52‑week high of €292.85 hit earlier in June.
Technical traders are watching the €236 level on a closing basis; if it holds, the intermediate downtrend is broken. The relative strength index sits near 56, leaving room for further upside — but also for a pullback if momentum fades.
The biggest risk, however, is execution. IBM’s own internal research shows that many corporate managers don’t fully track their AI dependencies and view vendor lock‑in as a problem. That could slow the rollout of large AI projects and dampen monetization of watsonx, the company’s flagship AI platform. The real test comes on July 22, 2026, when IBM reports quarterly earnings. Accelerated growth in software and AI platforms would reinforce the current rally. A miss, and the chip‑driven hype could evaporate as quickly as it appeared.
Ad
IBM Stock: Buy or Sell?! New IBM Analysis from June 27 delivers the answer:
The latest IBM figures speak for themselves: Urgent action needed for IBM investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 27.
IBM: Buy or sell? Read more here...
